

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶: A61K 9/00, 47/36	A1	(11) International Publication Number: WO 00/30609 (43) International Publication Date: 2 June 2000 (02.06.00)
(21) International Application Number: PCT/IB98/01886 (22) International Filing Date: 20 November 1998 (20.11.98) (71) Applicant (for all designated States except US): LABORATOIRE MEDIDOM S.A. [CH/CH]; 24, avenue de Champel, CH-1206 Geneva (CH). (72) Inventors; and (75) Inventors/Applicants (for US only): GURNY, Robert [CH/CH]; 7, rue Calvin, CH-1204 Geneva (CH). FELT, Olivia [FR/FR]; 249, route du Fer-à-Cheval, F-74160 Collonges sous Salève (FR). (74) Agent: WILLIAM BLANC & CIE CONSEILS EN PROPRIETE INDUSTRIELLE S.A.; 9, rue du Valais, CH-1202 Genève (CH).	(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>	
(54) Title: AQUEOUS OPHTHALMIC FORMULATIONS COMPRISING CHITOSAN (57) Abstract A use of chitosan salt is disclosed, said salt having a deacetylation degree of 50 - 90 % and a molecular weight of 80,000 - 5,000,000 Da for the preparation of an aqueous ophthalmic formulation to be used as artificial tears having antimicrobial activity. The chitosan salt is used in an amount of 0.05 - 3 wt/v % based on the total aqueous ophthalmic formulation, said ophthalmic formulation having a viscosity of 10 - 500 mPa.s and a physiologically acceptable pH. The artificial tears obtained are particularly advantageous to treat dry eye syndrome and to prevent and cure infections or surinfections inherent to the treatment of dry eye.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

AQUEOUS OPHTHALMIC FORMULATIONS COMPRISING CHITOSAN

The invention relates to an aqueous ophthalmic formulation containing a chitosan salt for use as artificial tears having antimicrobial activity and to the use of a chitosan salt for preparing an aqueous ophthalmic formulation for use as artificial tears having an antimicrobial activity.

Normal tears are a complex combination of substances which form three layers on the eye.

A very thin outer oily layer contains lipids from the meibomina glands in the eyelid, to reduce evaporation.

A thick middle watery layer, produced by the lachrymal glands, keeps the salinity and the acidity of the tears at proper level and also carries antibodies and other immune defense agents to defend the eye against infection.

A very thin inner mucus layer helps maintaining a stable tear film.

Dry eye syndrome, which is the decline of the quality or quantity of tears bathing the eye, can lead if untreated to scarring or ulceration of the cornea, and thus loss of vision.

In many case, dry eye results from disorders of the various glands which work together to produce normal tears.

CONFIRMATION COPY

The dry eye syndrome may result of a very large range of causes such as aging, diseases and side effects of diseases, medications, contact lenses, environmental conditions, computer uses, and so one.

Artificial tears are the most common form of treatment for dry eye symptoms.

Artificial tears which are available at the present time contain generally as the major component glycerine, carboxymethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, polyvinylalcohol or hyaluronic acid salts.

For example, EP-A-0,698,388 discloses an ophthalmic preparation for use as artificial tears containing hyaluronic acid salts as a viscosity thickener.

A frequent complication of dry eye is the appearance of infections due to the reduced quantity of lysozyme, one of the natural infection-fighting components present in the tears.

Another well known cause of surinfection is that unit-doses of artificial tears are often badly used by patients who prefer to keep the same dose for 2, 3 or more consecutive instillations than discard it as recommended, thus causing an infection or aggravating an existing infection.

Also known are problems of tolerance in relation with the quantity and/or the nature of active ingredients and/or preservatives contained in the artificial tears, because the treatment of dry eye with artificial tears is generally prescribed for a prolonged period which can be for life.

An object of the present invention is to provide an aqueous ophthalmic formulation for use as artificial tears which can be administrated to the eye in convenient drop

form, and which prevents and cures infections or surinfections inherent to the treatment of dry eye by artificial tears without problems of tolerance even for a prolonged use.

According to the present invention, this object has been achieved as a result of the unexpected findings that an aqueous composition containing a very low concentration of chitosan salt can be useful as artificial tears having antimicrobial efficacy when administered in convenient drop form to the eye.

Chitosan is known as a chitin derivative obtained by partial to substantial deacetylation of chitin also named poly(N-acetyl-D-glucosamine), which is a naturally occurring biopolymer found in shellfish.

Chitosan contains free amine ($-NH_2$) groups and may be characterized as to the proportion of N-acetyl-D-glucosamine units and D-glucosamine units, and such is expressed as the degree of deacetylation of the fully acetylated polymer chitin.

Chitosan is known to have numerous pharmaceutical activities.

EP-A-0,356,060 discloses compositions for use in the treatment of wounds such as dermal ulcers, said compositions containing chitosan which show a combination of antimicrobial activity and wound healing capability. Under the conditions tested, bacteriostatic activity is reported to be observed beginning with a 0.5 % concentration of chitosan malate. However, bactericidal activity is reported to be obtained only with compositions containing 10 % or more of chitosan malate.

US-A-5,015,632 discloses that chitosan pyrithione has an antimicrobial activity against a number of strains tested, including *Staphylococcus aureus*, equivalent to that of sodium pyrithione but that chitosan acetate was not effective against the strains tested.

US-A-5,422,116 discloses that chitosan is useful for preparing a liquid ophthalmic aqueous sustained release delivery system which provides a slow and sustained release of the treating agents incorporated therein to the eye. A list of antibacterian agents which could be incorporated in the formulation as treating agent against infections is disclosed.

According to one aspect, the present invention provides an aqueous ophthalmic formulation for use as artificial tears having antimicrobial activity, said aqueous ophthalmic formulation comprising 0.05 – 3 wt/v % of a chitosan salt having a deacetylation degree of 50 – 90 % and a molecular weight of 80,000 – 5,000,000 Da, said aqueous ophthalmic formulation having a viscosity of 10 – 500 mPa.s and a physiologically acceptable pH.

According to another aspect, the present invention has for object the use of a chitosan salt having a deacetylation degree of 50 – 90 % and a molecular weight of 80,000 – 5,000,000 Da for the preparation of an aqueous ophthalmic formulation for use as artificial tears having antimicrobial activity, the chitosan salt being used in an amount of 0.05 – 3 wt/v % based on the total aqueous ophthalmic formulation, said aqueous ophthalmic formulation having a viscosity of 10 – 500 mPa.s and a physiologically acceptable pH.

The present invention provides an aqueous ophthalmic formulation containing low concentration of chitosan salt for use as artificial tears having antimicrobial efficacy without further addition of an antimicrobial agent when administered in convenient drop form to the eye, which can prevent and cure infections or surinfections inherent to the treatment of dry eye by artificial tears even if unit doses are badly used as mentioned above, and which can be used without problems of tolerance even during a prolonged treatment such as for life.

An advantage of the use of chitosan under its salt form is that an addition of diluted acids, such as hydrochloric or acetic acids, to solubilize the chitosan having free amine groups is not required in the preparation of the ophthalmic formulation.

Other advantages of the present invention will appear in the following detailed description.

It is to be noted that in the present description and claims, the term "chitosan salt" means a chitosan containing ammonium ($-\text{NH}_3^+$) groups with corresponding counterions (X^-) instead of free amine ($-\text{NH}_2$) groups.

It is also to be noted that, as for chitosan, the "degree of deacetylation" in a sample of chitosan salt means the relative amounts of N-acetyl-D-glucosamine units and D-glucosammonium salt units present in the chitosan sample, and is expressed as the degree of deacetylation of the fully acetylated polymer chitin.

In the present invention, the term "antimicrobial activity" means both bactericidal and bacteriostatic activity.

The present invention will be now described in a more detailed manner.

Chitosan salt as used in the present invention is a chitosan salt having a counterion X^- derived from an inorganic or organic acid and having a deacetylation degree of 50 – 90 % and a weight average molecular weight of 80,000 – 5,000,000 Da.

Chitosan salt in various forms which can be used in the present invention is commercially available or can be prepared by a process based on deacetylation of chitin until the desired deacetylation degree, e.g. as described by Roberts, G.A.F., in

"Chitin chemistry", Mc Millan Press LTD, Houndmills, p. 64-82 (1992), to obtain a chitosan including free amine groups, and addition of an organic or inorganic acid to the chitosan to convert the free amine ($-NH_2$) groups of chitosan into ammonium ($-NH_3^+$) groups with corresponding counterions (X^-), thus converting the chitosan into chitosan salt thereof, e.g. as described by Muzarelli, R.A., in "Natural chelating polymers", Pergamon Press, Oxford, p. 150-156 (1973). Commercial sources of chitosan salts are for example Pronova® Biopolymer, Drammen, Norway; Vanson Company, Redmond, Washington, USA; Nova Chem Limited, Armdale, Halifax, Nova Scotia, Canada; Biosynth A.G., Staad, Switzerland; Biopolymer Engineering, Inc., St-Paul, Minnesota, USA.

The weight average molecular weight of chitosan salt used in the present invention may be determined by size exclusion chromatography as mentioned hereafter.

Chitosan salts of molecular weights lower than 80,000 Da are not appropriate for use in the present invention because required viscosity may be not obtained.

Chitosan salts of molecular weights greater than 5,000,000 Da are not advantageous since they imply high manufacturing costs and also since they form very stiff gels which cannot be easily and reproducibly applied.

Preferably, the chitosan salt used in the present invention has a molecular weight of 160,000 – 580,000 Da.

The deacetylation degree of chitosan salts may be determined by a spectrophotometric method such as described in the literature by Muzarelli, R.A. and Ricchetti, R., in Carbohydr. Polym. 5, p. 461-472, 1985 or Muzarelli, R.A. and Ricchetti, R. in "Chitin in Nature and Technology", Plenum Press, p. 385-388, 1986.

Chitosan salt for use in the present invention has a deacetylation degree of 50 – 90% which means that the chitosan salt comprises 50 – 90 % of D-glucosammonium units with corresponding counterions and 50 – 10 % of N-acetyl-D-glycosamine units, respectively.

Preferably, chitosan salt as used in the present invention has a deacetylation degree of 83 % to 87 %.

For the purpose of the present invention, particularly preferred chitosan salts are chitosan hydrochloride and chitosan glutamate.

The aqueous ophthalmic formulation of the present invention comprises from 0.05 to 3 wt/v % of chitosan salt.

A formulation having a content of chitosan salt lower than 0.05 wt/v % is not appropriate for use as artificial tears having antimicrobial activity because the precorneal residence time becomes too short and the bactericidal effect becomes non-significant.

A formulation having a content of chitosan salt greater than 3 wt/v % is not appropriate for use as artificial tears because the presence of chitosan salt at this concentration may cause undesired side-effects such as irritation and intolerance.

Preferably, the chitosan salt is used in an amount of 0.5 to 1.5 wt/v %, based on the total aqueous ophthalmic formulation.

The aqueous ophthalmic formulation of the present invention has a viscosity of 10 – 500 mPa.s.

An ophthalmic formulation having a viscosity lower than 10 mPa.s is not advantageous for use as artificial tears because the precorneal residence time of the formulation becomes too short.

A formulation having a viscosity higher than 500 mPa.s is not appropriate for use as artificial tears because it forms a too stiff gel to be readily applied.

A particularly preferred ophthalmic formulation has a viscosity of 10 to 100 mPa.s.

For the purpose of the invention, the concentration of chitosan salt is adjusted according to the molecular weight and deacetylation degree of the chitosan salt used and according to the desired viscosity of the aqueous ophthalmic formulation.

It is to be noted that the aqueous ophthalmic formulation of the present invention has a Newtonian rheological behaviour.

According to the present invention, the aqueous ophthalmic formulation has a physiologically acceptable pH, preferably a pH of 5.4 – 7.0.

The osmolality of the aqueous ophthalmic formulation of the present invention ranges from 240 to 340 mosm/kg thus providing physiological acceptance.

The aqueous ophthalmic formulation of the present invention may be prepared according to conventional techniques by solubilizing the chitosan salt in the appropriate amount in a phosphate buffer solution (PBS) pH 7.4.

The aqueous ophthalmic formulation of the present invention can in particular be packaged as monodose units.

The aqueous ophthalmic formulation of the present invention has an antimicrobial activity against all bacteria which are sensitive to chitosan, in particular gram negative strains and gram positive strains, such as E.coli and S. aureus.

It is to be noted that the antimicrobial activity against S. aureus strains is particularly advantageous since it is known that such strains are very resistant and cause numerous problems in hospitals. It is to be noted that S. aureus is very often implicated in eye bacterial infections (conjunctivitis).

The aqueous ophthalmic formulation of the present invention has a very good wetting effect and a long precorneal residence time, and is very well tolerated. It is therefore appropriate to be used as artificial tears for prolonged treatment.

Due to its antimicrobial activity, the aqueous ophthalmic formulation of the present invention is particularly useful for preventing and treating infections when administered as artificial tears.

The aqueous ophthalmic formulation of the present invention is also advantageously used as artificial tears in the treatments of dry eye syndrome, eye irritations caused by environmental conditions or contact lenses, keratoconjunctivitis sicca, Sjögren's syndrome bacterial infections on the surface of the eye or related anterior structures caused by bacteria which are sensitive to chitosan, and in the prophylaxis of the bacterial infections in case of trauma and before or after surgery of the eye.

The aqueous ophthalmic formulation of the present invention can be used for topical administration to the eye in drop form.

To illustrate the antimicrobial activity of the formulations of the present invention used as artificial tears, tests will now be described with reference to an example wherein chitosan hydrochloride is being used as the chitosan salt.

The chitosan hydrochloride tested is named UPCI 110 and provided by Pronova®Biopolymer, Drammen, Norway.

The molecular weight of the UPCI 110 tested has been determined by size exclusion chromatography, with a Waters 600 E apparatus, combined with an autosampler (Waters TM717plus) and a Waters 410 differential refractometer. The conditions of analysis were the following :

- Column : series of 4 columns Ultrahydrogel® (7.8x300)
- Temperature : 30°C
- Flow rate : 0.8 ml/min
- Eluent : acetate buffer pH 4.2

0.1 % solution of UPCI 110 in acetate buffer was injected five times. By this method, the molecular weight of UPCI 110 has been determined to be 160,000 Da.

The deacetylation degree of UPCI 110 has been provided by the supplier and has been verified to be 87 % by the spectrophotometric method described in the above mentioned literature by Muzarelli, R.A. and Ricchetti, R.

The rheological evaluation of UPCI 110 has been tested at three increasing concentrations (0.5 %, 1.0 % and 1.5 %).

Rheological measurements have been made with a Bohlin Rheometer CS equipped with a system of control of the temperature (CS ETO). Data have been obtained under the following conditions :

- Temperature : 25°C
- Measuring system : Cone-plate 4/40 LS
- Shear stress : 5.97E-2 Pa
- Oscillation test

The results are shown in the following TABLE 1.

TABLE 1

Concentration of UPCI 110 (%)	Viscosity ¹ (mPa.s)
0.5	10.0
1.0	17.4
1.5	30.7

¹Solution in a phosphate buffer solution (PBS) pH 7.4

Tolerance of formulations containing UPCI 110 has been tested on rabbits and evaluated by using a confocal laser scanning ophthalmoscope (CLSO® Zeiss, Germany) modified by a set of lenses to examine the cornea instead of the retina. The rabbits were instilled with 25 µl of the test solution 4 times a day during 3 days. After the last instillation, the rabbits were sedated with an intramuscular injection of ketamine HCl/xylazine). Then, 25 µl of sodium fluorescein solution 0.5% in PBS were instilled in the eye to be tested. Fluorescein allows the injured areas to be selectively marked. The eye was then rinsed during 1 minute with a NaCl 0.9% solution. Then,

the cornea was examined. Each aqueous ophthalmic solution was tested on 3 rabbits.

Corneal lesions after topical administration of ophthalmic solutions having different concentrations are expressed in percentage of corneal fluorescent areas.

The results are shown in the following TABLE 2.

TABLE 2

Concentration of UPCI 110 (%)	Corneal lesions (%)
0.5	6.8
1.0	10.2
1.5	12.3

Corneal lesions of less than 25 % are generally accepted as indicating a very good tolerance. The present results are therefore very satisfactory.

Clinical examination to evaluate discharge, corneal/conjunctival swelling or redness have confirmed CLSO results: formulations based on UPCI 110 were always very well tolerated.

Also, gamma scintigraphic studies on rabbits have shown that formulation of the present invention based on chitosan hydrochloride have a precorneal residence time longer than PBS or normal saline.

It is to be noted that the precorneal residence time can be increased by increasing the molecular weight or the concentration of the chitosan salt in the formulation, i.e. by increasing the viscosity of the formulation.

The evaluation of the antimicrobial efficacy of chitosan hydrochloride UPCI 110 has been tested against *E. Coli* strains which are representative of gram negative bacteria and against gram *S. aureus* strains which are representative of gram positive bacteria.

E. Coli strains used in the tests were isolated from clinical specimens in the University of Geneva.

S. aureus strains used in the tests were ATCC 25 925 obtained from the collection of Institut Pasteur (Paris, France).

The solutions tested and the conditions of test were as follows.

The solutions were prepared by serial dilutions from 300 μ l to 10 μ l of a solution containing 0.5% of chitosan hydrochloride of the type UPCI 110 in phosphate buffer solution (PBS) pH 7.4, completed ad 1.0 ml with the bacterial strains in suspension in a liquid medium (Brain-Heart-Infusion = BHI). Controls were phosphate buffer solution (PBS) pH 7.4 and artificial tear commercial solution (Protagent® Unit-dose), and the volumes used were the same as the chitosan hydrochloride based solutions.

Each solution was incubated during 18 hours at 37°C.

After incubation, 50 μ l of each solution were sprayed on solid plates (medium Mueller-Hinton 2) after appropriate dilution and left for incubation during 24 hours for

bacterial counting. The number of bacteria suspended in BHI were counted before adding a solution.

The antimicrobial efficacy was determined twice for each bacterial strain.

The results of antimicrobial efficacy of UPCI 110 against E. Coli strains are shown in the following TABLE 3.

TABLE 3

Solution tested	Volume (μl)	Concentration of UPCI 110 (wt/v %)	Number of bacteria
UPCI 110	300	0.15	0
	150	0.075	0
	75	0.0375	80,000
	30	0.015	1.8×10^6
	10	0.005	2.8×10^6
PBS	300	0	1.4×10^{10}
	150	0	1.8×10^{10}
	75	0	1.2×10^{10}
	30	0	1.0×10^{10}
	10	0	1.2×10^9

The number of bacteria present in the liquid medium (BHI) at the beginning of the test was 80,000.

The results of antimicrobial efficacy of UPCI 110 against *S. aureus* strains are shown in the following TABLE 4.

TABLE 4

Solution tested	Volume (μl)	Concentration of UPCI 110 (wt/v %)	Number of bacteria
UPCI 110	300	0.15	2,000
	150	0.075	3,000
	75	0.0375	22,000
	30	0.015	9.4×10^5
	10	0.005	2.4×10^9
PBS	300	0	4.3×10^8
	150	0	8.8×10^8
	75	0	4.7×10^8
	30	0	3.8×10^8
	10	0	1.1×10^9
Protagent SE ®	300	0	8.4×10^8
	150	0	7.0×10^8
	75	0	2.2×10^8
	30	0	6.8×10^8
	10	0	2.1×10^9

The number of bacteria present in the liquid medium(BHI) at the beginning of the test was 1.35×10^6 .

The above antimicrobial efficacy tests show the following.

In case of E. Coli, the bactericidal effect of the tested solution at concentrations of chitosan salt down to 0.0375 is clearly apparent, since in the presence of 0.0375% of chitosan salt, the number of bacteria (80,000) is the same as the number of bacteria suspended in BHI. At even lower concentrations, the solution still has a marked bacteriostatic effect, as shown by the controls.

In the case of S. aureus, the limit between the bactericidal and bacteriostatic effects is situated between concentrations of 0.005 and 0.015 % of chitosan.

In both cases, controls show that the volumes tested do not interfere with the nutritious medium (BHI), since bacteria can grow normally. Bacterial growth is similar in the commercial Protagent ® Unit-dose and in the phosphate buffer solution (PBS).

The following examples of aqueous ophthalmic formulations of the present invention are given for illustrative purposes and are not intended to limit the scope of the invention.

EXAMPLES

Example 1

2.5 g of chitosan hydrochloride UPCI 110 as referred above, having a molecular weight of 160,000 Da and a deacetylation degree of 87 %, is solubilized in 500 ml of a phosphate buffer solution (PBS) pH 7.4, at room temperature under magnetic stirring. The resulting aqueous ophthalmic formulation contains 0.5 % of chitosan hydrochloride, has a viscosity of 10 mPa.s, a pH of 5.47, and an osmolality of 290 mosm/kg.

Example 2

7.5 g of chitosan hydrochloride UPCI 110 as referred above, having a molecular weight of 160,000 Da and a deacetylation degree of 87 %, is solubilized in 500 ml of

a phosphate buffer solution (PBS) pH 7.4, at room temperature under magnetic stirring. The resulting aqueous ophthalmic formulation contains 1.5 % of chitosan hydrochloride, has a viscosity of 30.7 mPa.s, a pH of 5.48, and an osmolality of 290 mosm/kg.

Example 3

5.0 g of chitosan glutamate UPG 210 obtained from Pronova®Biopolymer, Drammen, Norway, having a molecular weight of 580,000 Da and a deacetylation degree of 83 %, is solubilized in 500 ml of a phosphate buffer solution (PBS) pH 7.4, at room temperature under magnetic stirring. The resulting aqueous ophthalmic formulation contains 1.0 % of chitosan glutamate, has a viscosity of 54.5 mPa.s, a pH of 5.48 and an osmolality of 290 mosm/kg.

The formulations of Examples 1 and 2 may be packaged either in monodose units or in appropriate containers.

The formulations of Examples 1, 2 and 3 may be topically administered by instillation in the eye in convenient drop form.

CLAIMS

1. An aqueous ophthalmic formulation for use as artificial tears having antimicrobial activity, said ophthalmic formulation comprising 0.05 – 3 wt/v % of a chitosan salt having a deacetylation degree of 50 – 90 % and a molecular weight of 80,000 – 5,000,000 Da, said ophthalmic formulation having a viscosity of 10 – 500 mPa.s and a physiologically acceptable pH.
2. The aqueous ophthalmic formulation according to claim 1, wherein the chitosan salt has a molecular weight of 160,000 – 580,000 Da.
3. The aqueous ophthalmic formulation according to claim 1 or 2, wherein the chitosan salt has a deacetylation degree of 83 – 87 %.
4. The aqueous ophthalmic formulation according to any one of claims 1 to 3, wherein the chitosan salt is chitosan hydrochloride or chitosan glutamate.
5. The aqueous ophthalmic formulation according any one of claim 1 to 4, said aqueous ophthalmic formulation comprising 0.5 – 1.5 wt/v % of the chitosan salt.
6. The aqueous ophthalmic formulation according any one of claims 1 to 5, said ophthalmic formulation having a viscosity of 10 – 100 mPa.s.
7. The aqueous ophthalmic formulation according any one of claims 1 to 6, said ophthalmic formulation having a pH of 5.4 – 7.0.

8. The aqueous ophthalmic formulation according to any one of claims 1 to 7, being packaged as monodose units.
9. The aqueous ophthalmic formulation according to any one of claims 1 to 8, having an antimicrobial activity against bacteria which are sensitive to chitosan.
10. The aqueous ophthalmic formulation according to claim 9, wherein said bacteria are E.coli or S. aureus strains.
11. The aqueous ophthalmic formulation according to any one of claims 1 to 10, wherein said artificial tears are used in the treatment of dry eye syndrome.
12. The aqueous ophthalmic formulation according to any one of claims 1 to 10, wherein said artificial tears are used in the treatment of eye irritations caused by environmental conditions or contact lenses.
13. The aqueous ophthalmic formulation according to any one of claims 1 to 10, wherein said artificial tears are used in the treatment of keratoconjunctivitis sicca.
14. The aqueous ophthalmic formulation according to any one of claims 1 to 10, wherein said artificial tears are used in the treatment of Sjögren's syndrome.
15. The aqueous ophthalmic formulation according to any one of claims 1 to 10, wherein said artificial tears are used in the treatment of bacterial infections on the surface of the eye or related anterior structures caused by bacteria which are sensitive to chitosan.

16. The aqueous ophthalmic formulation according to any one of claims 1 to 10, wherein said artificial tears are used in the prophylaxis of the bacterial infections in case of trauma and before or after surgery of the eye.

17. A use of a chitosan salt having a deacetylation degree of 50 – 90 % and a molecular weight of 80,000 – 5,000,000 Da for the preparation of an aqueous ophthalmic formulation for use as artificial tears having antimicrobial activity, the chitosan salt being used in an amount of 0.05 – 3 wt/v % based on the total aqueous ophthalmic formulation, said ophthalmic formulation having a viscosity of 10 – 500 mPa.s and a physiologically acceptable pH.

18. The use according to claim 17, wherein said chitosan salt has a molecular weight of 160,000 – 580,000 Da.

19. The use according to claim 17 or 18, wherein said chitosan salt have a deacetylation degree of 83 – 87 %.

20. The use according to any one of claims 17 to 19, wherein the chitosan salt is chitosan hydrochloride or chitosan glutamate.

21. The use according to any one of claims 17 to 20, wherein said chitosan salt is used in an amount of 0.5 – 1.5 wt/v % based on the total aqueous ophthalmic formulation.

22. The use according to any one of claims 17 to 21, wherein said ophthalmic formulation has a viscosity of 10 – 100 mPa.s.

23. The use according to any one of claims 17 to 22, wherein said ophthalmic formulation has a pH of 5.4 – 7.0.

24. The use according to any one of claims 17 to 23, wherein the aqueous ophthalmic formulation is used as monodose units.

25. The use according to any one of claims 17 to 24, wherein the aqueous ophthalmic formulation has antimicrobial activity against bacteria which are sensitive to chitosan.

26. The use according to claim 25, wherein said bacteria are E.coli or S. aureus strains.

27. The use according to any one of claims 17 to 26, wherein said artificial tears are used in the treatment of dry eye syndrome.

28. The use according to any one of claims 17 to 26, wherein said artificial tears are used in the treatment of eye irritations caused by environmental conditions or contact lenses.

29. The use according to any one of claims 17 to 26, wherein said artificial tears are used in the treatment of keratoconjunctivitis sicca.

30. The use according to any one of claims 17 to 26, wherein said artificial tears are used in the treatment of Sjögren's syndrome.

31. The use according to any one of claims 17 to 26, wherein said artificial tears are used in the treatment of bacterial infections on the surface of the eye or related anterior structures caused by bacteria which are sensitive to chitosan.

32. The use according to any one of claims 17 to 26, wherein said artificial tears are used in the prophylaxis of the bacterial infections in case of trauma and before or after surgery of the eye.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/IB 98/01886

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A61K9/00 A61K47/36

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 377 091 A (SOCIETE DES PRODUITS NESTLE) 11 July 1990	1-8, 10, 17-23, 25, 26
Y	see claims 1-3, 10-13 see page 2, line 33 - line 44 see page 3, line 52 - page 4, line 5	1-32
Y	US 5 422 116 A (SHAU-FONG YEN, ET AL.) 6 June 1995 cited in the application see claims 1, 16 see column 2, line 49 - column 3, line 3 see column 3, line 28 - line 40	1-32

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

9 June 1999

Date of mailing of the international search report

15/06/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Ventura Amat, A

INTERNATIONAL SEARCH REPORT

Information on patent family members

Intern: 31 Application No

PCT/IB 98/01886

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 377091 A	11-07-1990	CH 675535 A	15-10-1990
		AT 88087 T	15-04-1993
		DK 526289 A	29-05-1990
		ES 2054979 T	16-08-1994
		JP 2193906 A	31-07-1990
		PT 92414 A	31-05-1990
		RU 2028138 C	09-02-1995
		US 5057542 A	15-10-1991
US 5422116 A	06-06-1995	AU 704353 B	22-04-1999
		AU 1464995 A	04-09-1995
		CA 2181715 A	24-08-1995
		CN 1140988 A	22-01-1997
		EP 0744938 A	04-12-1996
		FI 963217 A	16-08-1996
		WO 9522315 A	24-08-1995
		JP 9509166 T	16-09-1997
		NO 963431 A	09-10-1996
		NZ 278668 A	26-01-1998
		ZA 9501323 A	18-08-1995